Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Successful CTO reduces local and remote residual ischemia

Courtesy of Dr. Carlos Fava.

The presence of Chronic Total Occlusion (CTO) is about 30%, with an ischemic threshold between 10% and 12.5% to justify rechannelization. Using the new devices, the new guidelines and with more experience operators, these procedures are successful in 10% to 30% of cases.

Successful CTO Reduces Local and Remote Residual Ischemia

More often than not these patients are not treated because physicians will not see the benefit of treating this condition. Indeed, how we should treat these patients remains under debate.

 

The present prospective study included 69 patients undergoing successful CTO percutaneous coronary intervention (PCI). Patients received pre-procedural treatment and, after 12 weeks, a gadolinium enhancement cardiac magnetic resonance imaging (LGE-CMR). In addition, they received a positron emission tomography (PET) to assess absolute myocardial blood flow (MBF) with and without stress, and systolic function recovery.

 

Mean age was 63 (mostly men); BMI was 27.5 km/m2; HTA 34 patients; DLP 28; DBT 11; DLP 28; TBQ 22. Clinical presentation was: chronic stable angina 41, dyspnea 16 and silent ischemia 12.


Also read: “Successful PCI in older patients with chronic total occlusions reduces mortality”.


59 patients received CTO PCI exclusively and the remaining 10 PCI was associated to another vessel (it was not a case of CTO).

 

In the positron emission tomography after PCI, researchers observed an increase, mostly compared to baseline, in local and remote values of stress MBF (1.22±0.36 to 2.40±0.90 mL.min-1.g-1 p<0.001 and 2.58±0.68 to 2.77±0.77 mL.min-1.g-1 p=0.01).

MBF ratio between CTO and remote area increased between baseline and 12 weeks (0.49±0.13 vs. 0.87±0.24 p<0.001), and there was a reduction in defect CTO size after procedure (5.12±1.69 to 1.91±1.75 p<0.01).


Also read: “Is the transradial approach useful in chronic total occlusions?”


There was a significant increase in ejection fraction at follow up (46.4±11 vs. 47.5±11.4 p=0.01).

 

Conclusion

Most patients that had chronic total occlusion with ischemia and documented viability show significant improvement of stress MBF and reduced ischemia after successful PCI with minimal effect on ejection fraction.

 

Commentary

This analysis of successful OCT PCI in stable patients saw improved perfusion with minimal improvement in ventricular function.

 

It is difficult to analyze whether hard events such as mortality or AMI were reduced, since these are stable patients. We need several years of follow up to be able to see the actual benefit, given there might be several contradicting factors. 

 

What matters is knowing whether we will improve their quality of life. If we manage to reduce the need of drug treatment and que number of hospitalizations, we will reduce healthcare costs as well. 

 

Courtesy of Dr. Carlos Fava.

 

Original Title:Effect of successful percutaneous coronary intervention of chronic total occlusion on myocardial perfusion and left ventricular function.

Reference: Wijnand J. Stuijfzand et al. EuroIntervention 2017;13:345-354.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...